CN115175672B - 用于管理慢性阻塞性肺病的组合物 - Google Patents

用于管理慢性阻塞性肺病的组合物 Download PDF

Info

Publication number
CN115175672B
CN115175672B CN202180015345.2A CN202180015345A CN115175672B CN 115175672 B CN115175672 B CN 115175672B CN 202180015345 A CN202180015345 A CN 202180015345A CN 115175672 B CN115175672 B CN 115175672B
Authority
CN
China
Prior art keywords
increased
copd
alveolar
chronic obstructive
obstructive pulmonary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180015345.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN115175672A (zh
Inventor
M.马吉德
K.纳加布沙纳姆
S.巴尼
A.潘迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sami Sabinsha Group Co ltd
Original Assignee
Sami Sabinsha Group Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sami Sabinsha Group Co ltd filed Critical Sami Sabinsha Group Co ltd
Publication of CN115175672A publication Critical patent/CN115175672A/zh
Application granted granted Critical
Publication of CN115175672B publication Critical patent/CN115175672B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180015345.2A 2020-01-17 2021-01-16 用于管理慢性阻塞性肺病的组合物 Active CN115175672B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062962343P 2020-01-17 2020-01-17
US62/962,343 2020-01-17
US202063126920P 2020-12-17 2020-12-17
US63/126,920 2020-12-17
PCT/US2021/013763 WO2021146648A1 (en) 2020-01-17 2021-01-16 Compositions for managing chronic obstructive pulmonary disease

Publications (2)

Publication Number Publication Date
CN115175672A CN115175672A (zh) 2022-10-11
CN115175672B true CN115175672B (zh) 2024-07-02

Family

ID=76856592

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180015345.2A Active CN115175672B (zh) 2020-01-17 2021-01-16 用于管理慢性阻塞性肺病的组合物

Country Status (9)

Country Link
US (1) US11925606B2 (enExample)
EP (1) EP4090340B1 (enExample)
JP (1) JP7746272B2 (enExample)
KR (1) KR20220128382A (enExample)
CN (1) CN115175672B (enExample)
AU (1) AU2021207536B2 (enExample)
BR (1) BR112022014114A2 (enExample)
CA (1) CA3164013A1 (enExample)
WO (1) WO2021146648A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023554642A (ja) * 2020-12-17 2023-12-28 サミ－サビンサ グループ リミテッド ビスデメトキシクルクミン組成物の抗肥満能
WO2022203721A1 (en) * 2021-03-25 2022-09-29 Muhammed Majeed Compositions and methods for inhibiting proteolytic activation of viruses
RS20220433A1 (sr) 2022-05-11 2023-11-30 Milan Prokin Višeciljni antivirusni dodatak ishrani

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266883A1 (en) * 1999-10-27 2004-12-30 Yale University Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
US20100179103A1 (en) * 2008-07-21 2010-07-15 Ketan Desai Curcumin cyclodextrin combination for preventing or treating various diseases
US8486909B2 (en) * 2009-06-24 2013-07-16 Board Of Regents Of The University Of Nebraska Compositions and methods for the diagnosis and treatment of inflammatory disorders and fibrotic disease
EP2475380A1 (en) * 2009-09-11 2012-07-18 Protaffin Biotechnologie AG Composition for treatment of cxcl8-mediated lung inflammation
WO2012047674A2 (en) * 2010-09-27 2012-04-12 Microdose Therapeutx, Inc. Methods and compositions for disease treatment using inhalation
ITMI20132169A1 (it) * 2013-12-20 2015-06-21 Thompson S R L Composizione per la prevenzione ed il trattamento della bpco e della sintomatologia correlata
JP2017516764A (ja) * 2014-04-18 2017-06-22 オムニアクティブ ヘルス テクノロジーズ リミテッド クルクミン組成物及びその使用
WO2016145159A1 (en) * 2015-03-10 2016-09-15 The Research Foundation For The State University Of New York Chemically modified curcumins for use in the production of lipoxins
JP6688009B2 (ja) * 2015-04-15 2020-04-28 長谷川　浩二 酸化変性ｌｄｌ複合体抑制剤
CN105998043B (zh) * 2016-07-01 2018-11-27 吉林大学 槐属双苷在制备防治慢性阻塞性肺疾病药物中的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Multi-target natural products as alternatives against oxidative stress in Chronic Obstructive Pulmonary Disease (COPD)";Priscila Baltazar Gonçalves et al.;《European Journal of Medicinal Chemistry》;第163卷;第911-931页 *
"Structure-Based Virtual Screening Campaigns on Curcuminoids as Potent Ligands for Histone Deacetylase-2";Enade Perdana istyastono et al.;《Orient. J. Chem.》;第32卷(第1期);第275-282页 *

Also Published As

Publication number Publication date
US11925606B2 (en) 2024-03-12
CN115175672A (zh) 2022-10-11
AU2021207536B2 (en) 2025-04-10
CA3164013A1 (en) 2021-07-22
NZ790708A (en) 2025-05-02
WO2021146648A1 (en) 2021-07-22
BR112022014114A2 (pt) 2022-09-13
JP2023512489A (ja) 2023-03-27
AU2021207536A1 (en) 2022-08-11
KR20220128382A (ko) 2022-09-20
US20210220290A1 (en) 2021-07-22
EP4090340A1 (en) 2022-11-23
EP4090340B1 (en) 2026-05-06
EP4090340A4 (en) 2024-02-21
JP7746272B2 (ja) 2025-09-30

Similar Documents

Publication Publication Date Title
Xiong et al. PM2. 5-induced lung injury is attenuated in macrophage-specific NLRP3 deficient mice
Xu et al. Effect of compound sophorae decoction on dextran sodium sulfate (DSS)-induced colitis in mice by regulating Th17/Treg cell balance
JP7746272B2 (ja) 慢性閉塞性肺疾患を管理するための組成物
Shen et al. Chloroquine attenuates paraquat-induced lung injury in mice by altering inflammation, oxidative stress and fibrosis
Lee et al. Camellia japonica oil suppressed asthma occurrence via GATA-3 & IL-4 pathway and its effective and major component is oleic acid
Kashiwagi et al. Locally activated renin-angiotensin system associated with TGF-β1 as a major factor for renal injury induced by chronic inhibition of nitric oxide synthase in rats
Zuo et al. Luteolin relieved DSS-induced colitis in mice via HMGB1-TLR-NF-κB signaling pathway
Chauhan et al. Intranasal curcumin attenuates airway remodeling in murine model of chronic asthma
Said et al. Ameliorating effect of gum arabic and lemongrass on chronic kidney disease induced experimentally in rats
Chauhan et al. Intranasal curcumin inhibits pulmonary fibrosis by modulating matrix metalloproteinase-9 (MMP-9) in ovalbumin-induced chronic asthma
Kang et al. Dai-Huang-Fu-Zi-Tang alleviates pulmonary and intestinal injury with severe acute pancreatitis via regulating aquaporins in rats
Wang et al. Antifibrotic effect of Gancao Ganjiang decoction is mediated by PD-1/TGF-β1/IL-17A pathway in bleomycin-induced idiopathic pulmonary fibrosis
Vargas-Pozada et al. Caffeine mitigates experimental nonalcoholic steatohepatitis and the progression of thioacetamide-induced liver fibrosis by blocking the MAPK and TGF-β/Smad3 signaling pathways
Yang et al. Mitochondrial‐targeting antioxidant SS‐31 suppresses airway inflammation and oxidative stress induced by cigarette smoke
Shi et al. Mitochondrial dysfunction: an emerging link in the pathophysiology of cardiorenal syndrome
Yan et al. The application of proteomics and metabolomics to reveal the molecular mechanism of Nutmeg-5 in ameliorating cardiac fibrosis following myocardial infarction
Souza et al. Diminazene aceturate, an angiotensin-converting enzyme II activator, prevents gastric mucosal damage in mice: Role of the angiotensin-(1–7)/Mas receptor axis
Xie et al. Salvianolic acid A alleviates atherosclerosis by inhibiting inflammation through Trc8-mediated 3-hydroxy-3-methylglutaryl-coenzyme A reductase degradation
Hsu et al. Skin proteomic profiling of irradiation-induced fibrosis and its modulation by low molecular weight fucoidan via tight junction pathway
Zang et al. Protective effect of CD137 deficiency against postinfarction cardiac fibrosis and adverse cardiac remodeling by ERK1/2 signaling pathways
Yildirim et al. Aggravating effect of atorvastatin on indomethacin-induced gastric injury: Focus on PGE2, TNF-α, neutrophils and iNOS
CN110075117A (zh) 肝素钠作为抑制草鱼呼肠孤病毒感染药物的用途
CN104622886A (zh) 烟酰胺核糖在制备治疗非酒精性脂肪性肝炎的药物中的应用
Shehata et al. Morin attenuates sepsis-induced acute kidney injury by regulating inflammatory responses, oxidative stress and tubular regeneration (morin and sepsis-induced acute kidney injury)
Yu et al. Tanshinone IIA attenuates airway inflammation and airway remodeling in bronchial asthma by inhibiting p38/NF-κB and AKT/HIF-1α

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant